Key facts
- Abivax's experimental drug showed efficacy in a pivotal study for chronic inflammatory bowel disease.
- The study's results may prompt takeover offers for Abivax.
Positive results from pivotal studies are often catalysts for mergers and acquisitions in the pharmaceutical and biotechnology sectors, as they validate a drug's potential and increase a company's valuation.